INTRODUCTION
Human immunodefi ciency virus type 1 (HIV-1) infection starts from binding to the cell surface receptors. By fusing with cellular membrane or by endocytosis (Miyauchi et al., 2009) , the viral particle is delivered into the recipient cells. The singlestranded viral genomic RNA is reverse-transcribed into doublestranded DNA by reverse transcriptase, followed by integration of the viral DNA into host chromosome. Viral accessory proteins Tat, Rev and Nef are the fi rst produced viral proteins, whose nascent mRNAs in the nucleus are fully spliced by the cellular splicing machinery. Tat dramatically enhances the transcription, resulting in robust production of the viral RNAs. Rev modulates the splicing manner of viral transcripts and their exporting to the cytoplasm (Cochrane et al., 2006) . Singly spliced RNAs encode HIV-1 Vif, Vpu, Vpr and Envelope proteins. The full-length RNA encodes Gag and Gag-Pol polyproteins, and also serves as the viral genome for progeny virus. Gag and Gag-Pol proteins assemble at the plasma membrane, packaging two copies of full-length viral RNA to produce immature viral particles. Cleavage of Gag proteins by the viral protease restructures the viral particles into mature virions (Ramezani and Hawley, 2002) .
The HIV-1 genomic RNA is highly structured and very different from cellular mRNAs, rendering the viral RNA prone to attacks by the cellular RNA quality control system. For example, the 5′UTRs of multiply spliced viral mRNAs are targeted by zinc-fi nger antiviral protein (ZAP), which inhibits the translation and promotes the degradation of the viral mRNAs (Zhu et al., 2011) . The 3′UTR of HIV-1 genomic RNA, which is much longer than that of most cellular mRNAs, is associated with Upf1 in a length-dependent manner. Upf1 binding of the viral RNA promotes mRNA decay (Hogg and Goff, 2010) . How the virus protects its RNAs to establish effective replication is largely unknown.
Y-box-binding protein 1 (YB-1) is a DNA-and RNA-binding protein (Didier et al., 1988; Evdokimova et al., 1995) , involved in a variety of cellular activities, including activating target gene transcription, engaging in pre-mRNA splicing, and stabilizing mRNAs (Eliseeva et al., 2011) . YB-1 has been reported to interact with many viruses. It binds to the 3′UTR of Dengue Virus and inhibits the viral replication (Paranjape and Harris, 2007) , interacts with the NS3/4A of hepatitis C virus to regulate viral RNA replication and particle production (Chatel-Chaix et al., 2011) , and binds to the vRNP of infl uenza virus to increase progeny virus production (Kawaguchi et al., 2012) . We recently reported that YB-1 increases the production of Murine leukemia virus-based vector by increasing the stability of the viral RNAs in producer cells, thus the available gRNA for packaging (Li et al., 2012) .
In the present study, we show that YB-1 expression en-
RESULTS

Overexpression of YB-1 promotes HIV-1 production
To determine the effect of YB-1 expression on the production of HIV-1, a plasmid expressing YB-1 was co-transfected with the HIV-1 vector production constructs in HEK293T cells. Two HIV-1-based vectors were used, NL4-3luc and HR′luc (Zhu et al., 2011) . Both vectors carry fi refl y luciferase coding sequences substituting the nef gene in the genome, whose transcription is driven by HIV-1 LTR (Fig. 1A) . pNL4-3luc was derived from the wild-type HIV-1 isolate NL4-3, with a frame shift in the 5′end of the envelope coding sequence. Pseudotyped NL4-3luc can be produced by coexpression of pNL4-3luc and a plasmid expressing VSV-G, pVSV-G. To produce pseudotyped HR′luc, pHR′luc is co-expressed with pVSV-G and the plasmid pCMVΔR8.2, which expresses HIV-1 structural proteins (Gag), enzymes (Pol) and other accessory proteins (Fig. 1A) . At two days posttransfection, the supernatants were collected to infect recipient cells. The luciferase activity was measured in the HEK293T viral producing cells and in the recipient cells. Overexpression of YB-1 increased the luciferase activity expressed from both pNL4-3luc and pHR′luc in the producer cells (Fig. 1B) . In line with these results, the luciferase activity in the recipient cells infected with vectors produced in the presence of YB-1 was also increased (Fig. 1C) . To test whether YB-1 promotes the production of replication-competent HIV-1, we used NLenvLuc (Dang et al., 2008) , an infectious HIV-1 clone derived from wild-type NL4-3 with the luciferase coding sequences inserted into nef to facilitate virions detection. As expected, the expression of YB-1 increased the luciferase activity encoded by NLenvLuc in both producer cells and recipient cells (Fig.1D ). These results indicate that YB-1 expression enhances HIV-1 production.
Downregulation of YB-1 reduces HIV-1 production
To test whether endogenous YB-1 regulates the production of HIV-1, the expression of YB-1 was downregulated by RNA interference in the producer cells and the production of HIV-1 vectors was evaluated. Two shRNAs against YB-1 were constructed. The ability of the shRNAs to downregulate the expression of YB-1 was fi rst confi rmed by cotranfection of plasmids expressing the shRNA and Flag-tagged YB-1 in HEK293T cells ( Fig. 2A) . To analyze the effect of the downregulation of endogenous YB-1 on HIV-1 production, the shRNA against YB-1 was coexpressed with the NL4-3luc vector-producing constructs. The pseudoviruses were collected to infect recipient cells. Indeed, downregulation of endogenous YB-1 reduced the luciferase activity in both the producer cells (Fig. 2B ) and recipient cells (Fig. 2C) . The results indicate that endogenous YB1 facilitates HIV-1 production.
YB-1 stabilizes the viral genomic RNA
We next analyzed whether YB-1 enhances HIV-1 production through increasing the viral RNA levels. To analyze the viral genomic RNA levels in virion particles, the pseudovirus produced in the absence or presence of YB-1 were purifi ed and the viral genomic RNA was extracted. The viral genomic RNA levels were analyzed by RT-qPCR. Indeed, the RNA level in the virions produced from YB-1-expressing cells is signifi cantly higher than that from the control cells (Fig. 3A) . Consistently, expression of YB-1 significantly increased the viral genomic RNA levels in the producer cells (Fig. 3B) . The increase in the viral genomic RNA levels could result from increased transcription or mRNA stabilization. To test whether YB-1 enhances HIV-1 transcription in HEK293T cells, we used a fi refl y luciferase reporter system, in which the fi refl y luciferase gene transcription is driven by HIV-1 LTR (U3, R and U5). Data show that YB-1 failed to increase the luciferase activity in HEK293T cells with or without the presence of the viral transcription activator Tat (Fig. 3C ). These results suggest that in HEK293T cells, YB-1 does not increase the viral RNA level through enhancing viral transcription.
We next analyzed whether YB-1 stabilized the viral genomic RNA. A plasmid expressing YB-1 was cotransfected with pNL4-3luc. The global transcription was blocked by treatment of actinomycin D, and total RNA levels were measured by Northern blotting at different time points thereafter. Data show that the decay rate of the viral genomic RNA was signifi cantly reduced in the presence of YB-1 (Fig. 3D ), implicating that YB-1 expression stabilizes the viral genomic RNA.
Stem loop 2 of HIV-1 5′UTR is the target sequence of YB-1
YB-1 stabilized the viral genome RNA, which encodes Gag protein. Hence, YB-1 is expected to improve Gag protein levels in the producer cells. To test the idea, Gag expression was analyzed by Western blotting. In the NL4-3luc producer cells, Gag was translated from the viral genomic RNA while in the HR′-luc producer cells Gag was encoded by pCMVΔR8.2. Data show that in the cells producing NL4-3luc, Gag expression was significantly enhanced by YB-1. In contrast, in the cells producing HR′-luc, Gag expression was little affected (Fig. 4A) . Comparison between the sequences of pNL4-3luc and pCMVΔR8.2 reveals that pNL4-3luc contains the viral 5′ UTR upstream of the Gag coding sequence, which is absent in pCMVΔR8.2. To explore whether the 5′UTR is responsible for the difference between pNL4-3luc and pCMVΔR8.2 in the response to YB-1, it was cloned upstream of firefly luciferase coding sequence in the reporter, pGL3-linker (Guo et al., 2004) . The transcription of this luciferase reporter is driven by an SV40 promoter. Luciferase expression from pGL3-linker was not affected by YB-1. In contrast, luciferase expression from the reporter containing the HIV-1 5′UTR was signifi cantly increased (Fig. 4B) . These results suggest that the 5′UTR of HIV-1 is suffi cient to be targeted by YB-1. To further substantiate this notion, the Gag coding sequence with or without the COMMUNICATION Protein Cell & 5′UTR was cloned into pcDNA4/TO/myc-HisB vector (Fig. 4C) , and their response to YB-1 was analyzed. Indeed, expression of Gag from the coding sequence alone was not affected by YB-1. However, the expression of 5′UTR-Gag was signifi cantly enhanced by YB-1 (Fig. 4D) . These results indicate that the 5′UTR of HIV-1 is the responsive sequences to YB-1.
The 5′UTR of HIV-1 includes R, U5, primer binding site (PBS), and the packaging signal which is composed of stem loop 1 (SL1), stem loop 2 (SL2) and stem loop 3 (SL3). To further map the region responsive to YB-1, a series of deletion mutants were constructed (Fig. 4C) . Deletion from the 5′end up to SL1 (SL2-3-Gag) did not change the sensitivity to YB-1, while further deletion of SL2 (SL3-Gag) compromised the reporter′s sensitivity to YB-1 (Fig. 4D) . To determine whether SL2 is required for YB-1, SL2 was deleted in UTRGag [(-)SL2] (Fig. 4C) . The resulting Gag level from (-)SL2 was not affected by YB-1 (Fig. 4E) , indicating that SL2 is required for YB-1 to enhance Gag expression. To test whether SL2 is suffi cient, SL2 was cloned upstream of the luciferase coding sequence. Data show that the luciferase activity was increased by SL2 in the response to YB-1 (Fig. 4F) . Consistently, cloning of both SL2 and SL3 (SL23) upstream of the luciferase coding sequence increased luciferase expression in the presence of YB-1 (Fig. 4F) . These results indicate that SL2 is the target sequence for YB-1.
DISCUSSION
Here we report that the expression of YB-1 enhances HIV-1 production ( Fig. 1) while downregulation of endogenous YB-1 decreases viral production (Fig. 2) . Viral RNAs are stabilized by YB-1 (Fig. 3) . Comparison of different Gag expression vectors revealed that the HIV-1 5′UTR is required for YB-1 to enhance Gag expression. The stem loop 2 region in the packaging signal was further mapped to be the YB-1-targeting sequences (Fig. 4) .
It has been reported that in human astrocytic cell lines, YB-1 binds to both the TAR sequence and Tat protein to increase the activity of Tat, yet whether YB-1 increases HIV-1 production was not tested (Ansari et al., 1999) . In our assays, however, such stimulation was not observed (Fig. 2) . It is noted that here we used HEK293T cells, a cell line that is widely used to (Jenkins et al., 2010) . In the case of Dengue virus, YB-1 targets the RNA bearing the sequence 5′-UCCAGGCA-3′. The recently identifi ed YB-1 targeting sequence in MLV is in the R region. The HIV-1 SL2 sequence (5′-GGCGACTGGTGAGTACGCC-3′) identified here provides an additional target sequence of YB-1. However, alignment of these YB-1 targeting sequences displayed no significant sequence similarity. It is noted that for Dengue virus, YB-1 acts as an inhibitory factor repressing viral RNA translation. For MLV and HIV-1, YB-1 stabilizes viral mRNAs. What determines the outcome of YB-1 binding to its target RNA awaits further investigation. HIV-1 based lentivectors are widely used for gene transfer. The most commonly encountered problem is the low titer of the vectors. Our results indicated that overexpression of YB-1 enhances the production of HIV-1-based vectors. Such a strategy may be used in the preparation of lentivectors.
MATERIALS AND METHODS
Plasmids
The plasmid expressing Flag-tagged YB-1, pCMV-HF-YB-1, has been described previously (Li et al., 2012) . To generate the shRNAs directed against YB-1, oligonucleotides were designed and cloned into pSuper following the manufacturer′s instruction (OligoEgine). The sequences of the shRNAs directed against YB-1 are listed below: YB-1-3i F, 5′-GATC-CCCCCAGTTCAAGGCAGTAAATATTTCAAGAGAATATTTACTGC-CTTGAACTGGTTTTTA-3′; YB-1-3i R, 5′-AGCTTAAAAACCAGTTCAA-GGCAGTAAATATTCTCTTGAAATATTTACTGCCTTGAACTGGGGG-3′; YB-1-4i F, 5′-GATCCCCGACGGCAATGAAGAAGATAAATTCAAGAGA-TTTATCTTCTTCATTGCCGTCTTTTTA-3′; YB-1-4i R, 5′-AGCTTAAAAA-GACGGCAATGAAGAAGATAAATCTCTTGAATTTATCTTCTTCATT-GCCGTCGGG-3′.
HIV-1 producing plasmids pCMV-VSV-G, pHR′luc, pCMVΔR8.2 and pNL4-3luc have been described previously (Zhu et al., 2011) . pNLenvLuc was kindly provided by Dr. Yonghui Zheng of Michigan State University.
HIV-1 5′LTR, which is composed of U3, R and U5, was PCRamplified from pNL4-3luc and cloned into pGL3-Basic (Promega). The U3 region serves as a promoter for transcription of fi refl y luciferase and the R-U5 region in the mRNA serves as part of the 5′UTR. Primer sequences are listed below: LTR-F, 5′-GGTACCCTGGAA-GGGCTAATTCACTC-3′; LTR-R, 5′-CTCGAGCTGCTAGAGATTTTC-CACAC-3′.
HIV-1 5′UTR (R-U5-packaging signal) was PCR-amplified from pNL4-3luc and cloned into pGL3-linker (Guo et al., 2004) serving as the 5′UTR in the transcripts. Primer sequences are listed below: UTR-F, 5′-CCATGGGGTCTCTCTGGTTAGACCAG-3′; UTR-R, 5′-CCATG-GCTCTCTCCTTCTAGCCTCCG-3′
A fi refl y luciferase CDS was inserted into pcDNA4/TO/myc-HisB vector to generate pcDNA4-luc (luc), using XhoI and SacII sites. The fragments of HIV-1 SL2 and SL2-SL3 were annealed and inserted into pcDNA4-luc using BamHI and XhoI sites, to generate SL2-luc and SL2-SL3-luc (SL23-luc). The sequences are listed below: SL2, 5′-GGGCGGCGACTGGTGAGTACGCC-3′; SL23, 5′-GGGCGGC-GACTGGTGAGT ACGCCAAAAATTTTGACTAGCGGAGGCTAGAA-GGAGAGAG-3′ produce HIV-1 (Ramezani and Hawley, 2002) . The discrepancy between our results presented here and those previously reported by others suggest that YB-1 may behave differently in different cell lines.
YB-1 has been reported to be involved in pre-mRNA splicing (Hartmuth et al., 2002; Soop et al., 2003; Deckert et al., 2006) , mRNA translation (Evdokimova et al., 1995; Davydova et al., 1997; Evdokimova et al., 1998) and mRNA stabilization (Evdokimova et al., 2001 ). These functions rely on the ability of YB-1 to bind target RNA. The binding specifi city of YB-1 towards RNA is not strictly defi ned although it has been reported that YB-1 specifi cally stabilizes certain cellular mRNAs through (B and C) Plasmids pNL4-3luc and pVSV-G were cotransfected with the shRNA indicated into HEK293T cells. A plasmid expressing renilla luciferase was included to serve as a control for transfection effi ciency and sample handling. The luciferase activities in producer cells (B) and in recipient cells (C) were measured as described in the legend to Fig. 1 . Firefl y luciferase activity was normalized by renilla luciferase activity. The data are means + SD of three independent measurements. The relative luciferase expression level in control cells was set 1. HEK 293T cells (ATCC CRL-11268) were maintained in DMEM supplemented with 1% antibiotics and 10% fetal bovine serum (Invitrogen). Hela-CD4CCR5 cells have been described previously (Deng et al., 1996) .To produce pseudotyped HIV-1 vectors, the producing constructs were transfected into 293T cells. pRL-TK, a plasmid expressing renilla luciferase, was included to serve as a control for transfection effi ciency and sample handling. At 48 h post-transfection, producer cells were lysed with Passive Lysis Buffer (Promega) for dual-luciferase activity assay. The supernatants were collected and fi ltered through 0.45 μm fi lters (Millipore) to remove cell debris. The supernatants were then diluted three times with fresh medium for infection of 293T cells in the presence of polybrene at a fi nal concentration of 8 μg/mL. At 48 h post-infection, cells were lysed with Cell Culture Lysis Buffer (Promega) for luciferase activity measurement. For NLenvLuc vector production, pNLenvLuc was transfected into HEK293T cells. At 48h post-transfection, the supernatants were harvested to infect Hela-CD4CCR5 cells.
Measurement of viral RNA levels
The methods extracting virion RNAs and detecting RNA levels by realtime PCR has been described previously (Li et al., 2012) . The RNA Five segments of HIV-1 were PCR-amplifi ed from pNL4-3luc and cloned into pcDNA4/TO/myc-HisB vector (Invitrogen). The primers are listed below: UTRGag F, 5′-GCTCGGATCCGGTCTCTCTGGTTAGAC-CAG-3′; SL1-2-3 F, 5′-GCTCGGATCCGAGCTCTCTCGACGCAG-GAC-3′; SL2-3 F, 5′-GCTCGGATCCGGGCGGCGACTGGTGAG-TAC-3′; SL3 F, 5′-GCTCGGATCCAAAAATTTTGACTAGCGGAG-3′; GAG F, 5′-CTCGGATCCGCCACCATGGGTGCGAGAGCGTCAG -3′. The reverse primer is Gag R, 5′-AGACTCGAGTTATTGTGAC-GAGGGGTCGCT-3′.
To generate (-)SL2, two overlapping PCR fragments were mixed to serve as templates and PCR-amplified using primers UTRGag F and Gag R. The 5′ fragment was amplifi ed from pUTRGag using primers UTRGag F and (-)SL2 R. The 3′ fragment was amplifi ed from pUTRGag using primers (-)SL2 F and Gag R. The sequences were cloned into pcDNA4/TO/myc-HisB (Invitrogen) for protein expression. The primers are listed below: (-)SL2 F, 5′-GCACGGCAAGAGGC-GAGGGGCAAAAATTTTGACTAGCGGAG-3′; (-)SL2 R, 5′-CTC-CGCTAGTCAAAATTTTT GCCCCTCGCCTCTTGCCGTGC-3′ pCMV-HF-Tat (101 amino acids in length), which expresses HIV-1 Tat protein, was generated by cloning PCR-derived coding sequences of HIV-1 Tat into pCMV-HF vector (Guo et al., 2007) using BamHI and EcoRI sites. 
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